相关实验视频

Updated: May 7, 2025

Real-time Observation of the DNA Strand Exchange Reaction Mediated by Rad51

Real-time Observation of the DNA Strand Exchange Reaction Mediated by Rad51

Published on: February 13, 2019

来自同源重组修复途径的RAD51和RAD50遗传多态性与AML的疾病结果和器官毒性有关

Alireza Mohseni¹, Gholamreza Toogeh², Shahrbano Rostami³

¹Thalassemia Research Center, Hemoglobinopthy Institute, Mazandaran University of Medical Sciences, Sari, Iran.

|December 31, 2024

概括

在RAD50和RAD51同类重组修复 (HRR) 基因中的遗传变异与急性髓性白血病 (AML) 治疗结果有关. 这些发现表明,在AML治疗中,有可能进行个性化药物调整.

科学领域:

遗传学遗传学是一个
在瘤学瘤学.
分子生物学分子生物学

背景情况:

急性髓性白血病 (AML) 是一种复杂的癌症,对治疗的反应是可变的.
化疗在AML中的有效性受到DNA损伤反应 (DDR) 的影响.
同源重组修复 (HRR) 途径在DNA修复和基因组稳定性中起着至关重要的作用.

研究的目的:

研究HRR通路基因 (RAD51,XRCC3,NBS1,MRE11,RAD50) 中的特定遗传变异与AML患者的结果之间的关联.
确定这些变异是否与治疗反应,抗病性或器官毒性相关.

主要方法:

使用聚合酶链反应-限制片段长度多态 (PCR-RFLP) 对67例新诊断的AML病例进行基因定型.
通过桑格测序确认基因型定型结果.
基因变异的关联分析与临床结果和器官毒性,使用基平方测试.

主要成果:

携带RAD50 rs2299014变异基因的携带者对脏 (p=0.024) 和肝脏 (p=0.045) 毒性产生保护.
RAD50变异基因与增加的抗病能力有关 (p=0.001).
RAD51的rs1801320变体等位基因与对肝脏毒性的保护 (p=0.031) 和疾病耐药性 (p=0.012) 有关.

结论:

在RAD50 rs2299014和RAD51 rs1801320中的多态可能作为AML的预测生物标志物.
这些遗传变异可以为药物选择和剂量调整提供信息,以改善AML治疗策略.

关键词:

在急性髓性白血病中,急性骨髓性白血病化疗化疗是一种化学疗法.有机器毒性有机器毒性结果的结果.药物遗传学药物遗传学

更多相关视频

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Visualization of DNA Repair Proteins Interaction by Immunofluorescence

Published on: June 26, 2020

Author Spotlight: Decoding DNA Repair by Extrachromosomal NHEJ Assay and HR Assays

Author Spotlight: Decoding DNA Repair by Extrachromosomal NHEJ Assay and HR Assays

Published on: February 2, 2024

相关概念视频

Mismatch Repair

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

Mutagenicity and Carcinogenicity

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...

Nucleotide Excision Repair

Nucleotide Excision Repair

DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...